In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

I-Stat's $60 Million Gamble

Executive Summary

I-Stat, the pioneer in point-of-care diagnostics, is paying Abbott $60 million to break off a five-year-old distribution arrangement. That's a lot of money for a company that lost close to $60 million last year and has never made a dime. But i-Stat executives say it's the only way for their company to thrive and become profitable. The deal with Abbott never reached hoped-for sales goals, although Abbott met minimum targets. I-Stat has spent the better part of the past year shoring up its executive management team and building a sales and marketing infrastructure so that it can hit the ground running when the deal terminates in December.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel